ELZA founder Prof. Farhad Hafezi was one of two international guest speakers at the 31st Biennial Harvard Cornea Conference at the Schepens Eye Research Center at Harvard University in Boston, Massachusetts.
Dr. Emilio Torres-Netto’s moderated poster presentation “Stromal bed smoothness after excimer laser surface ablation as a key element for the expression of inflammatory genes”, which won the Best Poster Presentation Prize in the Refractive Surgery Section. Over 1000 posters were submitted to ESCRS; Torres-Netto et al.’s was considered to be the best.
The annual meeting of the European Society of Cataract and Refractive Surgeons (ESCRS) was held in Paris between 14–18 September 2019, and ELZA’s surgeons and researchers presented a record 21 presentations during the congress – so what did ELZA at ESCRS manage to achieve? Our team presented at 8 free paper presentations and a further 8 instructional courses, as well as three moderated poster sessions, two e-posters (as well as instructing in 1 wet lab too).
I was honoured to be invited to give a series of talks during this year’s MEACO congress, held in the Hilton Dead Sea & Spa Hotel in Amman, Jordan, where I reviewed the latest thinking in cross-linking and presented the latest clinical and laboratory research work from our research group and our collaborators.
ELZA’s medical director, Prof. Dr. Farhad Hafezi was invited to be the guest lecturer at the Croatian Ophthalmology and Optometric Society’s Contact Lens course, where he presented the latest corneal cross-linking (CXL) research and reviewed current best clinical practice for the treatment of keratoconus and iatrogenic ectasia.
“For most people, seeing a “cone” for the first time is quite surprising. They ask: How can the eye of someone be that shape? What
For the second year in a row, Dion Paridaens gave a series of lectures at the 2019 ESASO Course on Orbital, Lacrimal & Oculoplastic Surgery Course in Lugano, Switzerland (21–25 January, 2019).
Epi-on CXL aims to sidestep epi-off CXL’s issues by leaving the epithelium intact, however, this comes at a price of reduced efficacy – no clinical trial published to date has convincingly shown epi-on CXL to be as effective as epi-off CXL at the most important outcome: stopping keratoconus from progressing.
What is the future of corneal cross-linking (CXL)? PACK-CXL to treat corneal infections without antibiotics, refractive cross-linking and better Kpros…
The Cornea Society published a best practice review of CXL in the USA. Cross-linking is relatively new to the USA (but not Europe) – let’s get up to speed.
